Lupin receives EIR from US FDA for its Injectable Facility in Nagpur

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA), for drug-medical device combination products at its injectable facility in Nagpur, India. The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024.

Nilesh Gupta, Managing Director, Lupin said, "We are very pleased to have received the EIR from the US FDA for drug-device combination products at our Nagpur injectable facility. We remain committed to producing complex generic and essential products that address unmet needs."

Shares of Lupin Limited was last trading in BSE at Rs. 1936.75 as compared to the previous close of Rs. 1935.80. The total number of shares traded during the day was 54676 in over 5333 trades.

The stock hit an intraday high of Rs. 1960.95 and intraday low of 1922.10. The net turnover during the day was Rs. 106140664.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA EIR InjectableFacility Nagpur